{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:09:18Z","timestamp":1744344558555,"version":"3.40.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500202"],"award-info":[{"award-number":["2021YFC2500202"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04093-4","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:50:22Z","timestamp":1744285822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and dynamic changes of immune function of rituximab with mycophenolate mofetil in the treatment of steroid-dependent \/frequently relapsing nephrotic syndrome: a retrospective follow-up study"],"prefix":"10.1186","volume":"26","author":[{"given":"Songlei","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihui","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"10141","key":"4093_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61\u201374.","journal-title":"Lancet"},{"issue":"4S","key":"4093_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"issue":"4","key":"4093_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753\u201379.","journal-title":"Kidney Int"},{"issue":"8","key":"4093_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529\u201361.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4093_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","volume":"175","author":"P Ravani","year":"2021","unstructured":"Ravani P, Lugani F, Drovandi S, et al. Rituximab vs low dose mycophenolate mofetil in recurrence of steroid dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr. 2021;175(6):631\u20132. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.6150.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"4093_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00467-018-4145-6","volume":"34","author":"S Fujinaga","year":"2019","unstructured":"Fujinaga S, Nishino T, Umeda C, et al. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2019;34(2):353\u20137.","journal-title":"Pediatr Nephrol"},{"key":"4093_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1313-5","author":"K Iijima","year":"2016","unstructured":"Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2016. https:\/\/doi.org\/10.1007\/s10157-016-1313-5.","journal-title":"Clin Exp Nephrol"},{"key":"4093_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fped.2019.00178","volume":"7","author":"M Kallash","year":"2019","unstructured":"Kallash M, Smoyer WE, Mahan JD. Rituximab in the management of pediatric nephrotic syndrome. Front Pediatr. 2019;7:178. https:\/\/doi.org\/10.3389\/fped.2019.00178.","journal-title":"Front Pediatr"},{"issue":"12","key":"4093_CR9","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.2012030302","volume":"23","author":"C Wei","year":"2012","unstructured":"Wei C, Trachtman H, Li J, et al. Circulating SuPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23(12):2051\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4093_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, et al. Mycophenolate mofetil after rituximab for Childhood-Onset complicated Frequently-Relapsing or Steroid-Dependent nephrotic syndrome. JASN. 2022;33(2):401\u201319. https:\/\/doi.org\/10.1681\/ASN.2021050643.","journal-title":"JASN"},{"issue":"85","key":"4093_CR11","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.","journal-title":"Sci Transl Med"},{"key":"4093_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4095-z","author":"M Colucci","year":"2018","unstructured":"Colucci M, Carsetti R, Cascioli S, et al. B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol. 2018. https:\/\/doi.org\/10.1007\/s00467-018-4095-z.","journal-title":"Pediatr Nephrol"},{"key":"4093_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12519-020-00400-1","volume":"17","author":"J Chen","year":"2021","unstructured":"Chen J, Qiao XH, Mao JH. Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin. World J Pediatr. 2021;17:115\u201322. https:\/\/doi.org\/10.1007\/s12519-020-00400-1.","journal-title":"World J Pediatr"},{"key":"4093_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04609-0","author":"K Chan EYh, Tullus","year":"2020","unstructured":"Chan EYh, Tullus K. Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol IPNA. 2020. https:\/\/doi.org\/10.1007\/s00467-020-04609-0.","journal-title":"Pediatr Nephrol IPNA"},{"key":"4093_CR15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021111472","author":"E Chan","year":"2022","unstructured":"Chan E, Yu E, Angeletti A, et al. Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol. 2022. https:\/\/doi.org\/10.1681\/ASN.2021111472.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4093_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, et al. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016;31(1):89\u201395.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"4093_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, et al. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. 2017;21(4):671\u20136.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"4093_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","volume":"34","author":"J Hogan","year":"2018","unstructured":"Hogan J, Dossier C, Kwon T, et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2018;34(2):253\u20139.","journal-title":"Pediatr Nephrol"},{"key":"4093_CR19","doi-asserted-by":"publisher","unstructured":"Mason AE, Sen ES, Bierzynska A, et al. Response to first course of intensified immunosuppression in Genetically-Stratified steroid resistant nephrotic syndrome. CJASN. 2020;15. https:\/\/doi.org\/10.2215\/CJN.13371019.","DOI":"10.2215\/CJN.13371019"},{"key":"4093_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.1323","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, et al. Efficacy of rituximab vs tacrolimus in pediatric Corticosteroid-Dependent nephrotic syndrome A randomized clinical trial. JAMA Pediatr. 2018. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323.","journal-title":"JAMA Pediatr"},{"key":"4093_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04570-y","author":"JA Kari","year":"2020","unstructured":"Kari JA, Alhasan KA, Albanna AS, et al. Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol IPNA. 2020. https:\/\/doi.org\/10.1007\/s00467-020-04570-y.","journal-title":"Pediatr Nephrol IPNA"},{"issue":"1","key":"4093_CR22","first-page":"60","volume":"55","author":"\u0130 Giri\u015fgen","year":"2020","unstructured":"Giri\u015fgen \u0130, Y\u00fcksel S, Pekal Y. Rituximab experience in children with nephrotic syndrome: what have we observed differently. Turk Pediatri Ars. 2020;55(1):60\u20136. 14744\/Turk PediatriArs.2019.76148.","journal-title":"Turk Pediatri Ars"},{"key":"4093_CR23","doi-asserted-by":"publisher","unstructured":"Chan EYh, Webb H, Yu E et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney International. 2019. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","DOI":"10.1016\/j.kint.2019.09.033"},{"key":"4093_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.07.039","author":"D Chang","year":"2020","unstructured":"Chang D, Gong M, Liu C, et al. Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: A meta-analysis of randomized controlled trials. Med Clin (Barc). 2020. https:\/\/doi.org\/10.1016\/j.medcli.2020.07.039.","journal-title":"Med Clin (Barc)"},{"key":"4093_CR25","doi-asserted-by":"publisher","unstructured":"Colucci M, Carsetti R, Cascioli S, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2015;27. https:\/\/doi.org\/10.1681\/ASN.2015050523.","DOI":"10.1681\/ASN.2015050523"},{"key":"4093_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4095-z","author":"M Colucci","year":"2018","unstructured":"Colucci M, Carsetti R, Cascioli S, et al. B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol IPNA. 2018. https:\/\/doi.org\/10.1007\/s00467-018-4095-z.","journal-title":"Pediatr Nephrol IPNA"},{"key":"4093_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000511319","volume":"145","author":"C Ling","year":"2021","unstructured":"Ling C, Chen Z, Fan JF, et al. Decreased Circulating transitional B-Cell to memory B-Cell ratio is a risk factor for relapse in children with Steroid-Sensitive nephrotic syndrome. Nephron. 2021;145:107\u201312. https:\/\/doi.org\/10.1159\/000511319.","journal-title":"Nephron"},{"key":"4093_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.imlet.2021.07.006","volume":"238","author":"X Yang","year":"2021","unstructured":"Yang X, Man CM, Tang XX, et al. The disturbance and clinical signiffcance of B cell and Circulating follicular helper T cell subsets in children with primary nephrotic syndrome. Immunol Lett. 2021;238:32\u20139. https:\/\/doi.org\/10.1016\/j.imlet.2021.07.006.","journal-title":"Immunol Lett"},{"issue":"21","key":"4093_CR29","doi-asserted-by":"publisher","first-page":"e81836","DOI":"10.1172\/jci.insight.81836","volume":"2","author":"AHJ Kim","year":"2017","unstructured":"Kim AHJ, Chung J-J, Akilesh S, et al. B cell\u2013derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight. 2017;2(21):e81836. https:\/\/doi.org\/10.1172\/jci.insight.81836.","journal-title":"JCI Insight"},{"key":"4093_CR30","doi-asserted-by":"publisher","unstructured":"Boumediene A, Vachin P, Sendeyo K, et al. NEPHRUTIX: A randomized, double-blind, placebo vs rituximabcontrolled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun. 2017;1\u201312. https:\/\/doi.org\/10.1016\/j.jaut.2017.10.006.","DOI":"10.1016\/j.jaut.2017.10.006"},{"key":"4093_CR31","doi-asserted-by":"publisher","unstructured":"Chan CY, Liu ID, Resontoc LP, et al. T lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS. Clin J Am Soc Nephrol. 2016;11. https:\/\/doi.org\/10.2215\/CJN.11941115.","DOI":"10.2215\/CJN.11941115"},{"key":"4093_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12629","author":"L Zhang","year":"2017","unstructured":"Zhang L, Yan J, Yang B, et al. IL-23 activated \u0393\u03b4T cells affect Th17 cells and regulatory T cells by secreting IL-21 in children with primary nephrotic syndrome. The foundation for the Scandinavian. J Immunol. 2017. https:\/\/doi.org\/10.1111\/sji.12629.","journal-title":"J Immunol"},{"key":"4093_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.04.006","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Rosado MM, et al. Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome. Kidney Int. 2019. https:\/\/doi.org\/10.1016\/j.kint.2019.04.006.","journal-title":"Kidney Int"},{"key":"4093_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.trsl.2021.03.019","volume":"000","author":"CY CHAN","year":"2021","unstructured":"CHAN CY, TEO S, LU LJ, et al. Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. Translational Res. 2021;000:114. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.019.","journal-title":"Translational Res"},{"issue":"3","key":"4093_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.kint.2023.06.013","volume":"104","author":"M Colucci","year":"2023","unstructured":"Colucci M, Angeletti A, Zotta F, et al. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing\/steroid-dependent nephrotic syndrome. Kidney Int. 2023;104(3):577\u201386. https:\/\/doi.org\/10.1016\/j.kint.2023.06.013.","journal-title":"Kidney Int"},{"key":"4093_CR36","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.1038\/s41467-023-43504-8","volume":"14","author":"TA Al-Aubodah","year":"2023","unstructured":"Al-Aubodah TA, Aoudjit L, Pascale G, et al. The extrafollicular B cell response is a hallmark of childhood idiopathic nephrotic syndrome. Nat Commun. 2023;14:7682. https:\/\/doi.org\/10.1038\/s41467-023-43504-8.","journal-title":"Nat Commun"},{"issue":"4","key":"4093_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/ajprenal.00041.2021","volume":"321","author":"H Trachtman","year":"2021","unstructured":"Trachtman H, Laskowski J, Lee C, et al. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Ren Physiol. 2021;321(4):505\u201316. https:\/\/doi.org\/10.1152\/ajprenal.00041.2021.","journal-title":"Am J Physiol Ren Physiol"},{"key":"4093_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00467-020-04811-0","volume":"36","author":"C Dossier","year":"2021","unstructured":"Dossier C, Prim B, Moreau C, et al. A global AntiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. 2021;36:1175\u201382. https:\/\/doi.org\/10.1007\/s00467-020-04811-0.","journal-title":"Pediatr Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04093-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:50:23Z","timestamp":1744285823000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04093-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4093"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04093-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the Declaration of Helsinki. All procedures were approved by the medical ethics committee of Women and Children\u2019s Hospital, School of Medicine, Xiamen University (application number: KY-2024-114-K01). The parents were informed of the project aims and requirements. All participates were below 16 years in the study. Informed consent was obtained from the parents of the participants (below 16 year).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}